Nifty’s indicative price plunged 2% in two seconds during the closing auction session on monthly expiry, before recovering sharply. Analyst...

Indian stock markets tumbled significantly on Friday, with benchmark indices Sensex and Nifty recording considerable dips. The sharp surge ...

India's pharma and healthcare sector recorded 65 deals worth $13.9 billion in Q2 CY2026, with volumes falling 17% quarter-on-quarter to a f...

Markets remained range-bound, ending flat as consolidation continues with a positive bias above 25,400 for Nifty. SBI reported a 24% YoY ne...

Sudeep Pharma secured strong anchor investor participation ahead of its IPO, attracting major mutual funds, insurers and marquee investors,...

President Trump announced potential tariffs on imported pharmaceuticals, impacting countries like India, a major supplier to the US drug ma...

Funds like the Carlyle Group, Warburg Pincus and TA Associates are engaged in initial discussions, the people added. Investment bank O3 Cap...

"There are good expectations from the pharma basket in the run-up to the results."

‘The moratorium, which has been a niggling issue in the minds of investors, is turning out to be better than expected.’

ITI withdrew its follow-on public offer citing "prevailing market conditions".

RBI puts on hold Shanghvi Finance's request for core investment company licence.

Sudhir Valia to focus more on pursuits outside Sun, but continues to be a valuable resource for the company.

Shanghvi's brother-in-law and realty co owner Valia denies drugmaker stood guarantee for fundraising.

Here are a few stocks which may buzz the most in today's trade.

"It is indicative of the mood of the government that they want to open up."

The public-private partnership agreement is likely to be signed next week and will add funds to the National Framework for Malaria Eliminat...

Despite acquisitions, this year has been tough for Sun as the company has been battling quality issues in its own manufacturing facilities.